La Jolla Institute for Immunology

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

Retrieved on: 
Thursday, November 9, 2023
University of Los Andes (Colombia), IPO, Biogen, Therapy, Tajikistan State University of Law, Business, & Politics, Tree, Doctor of Philosophy, MBA, Engineering, HEC Paris, Central Executive Committee (PAP), Politics, Growth, Trinity College, Medicine, Paris, Executive Committee, Business, Senior, University of Hamburg, Ethicon, University, Trinity College Dublin, Sanofi, International communication, La Jolla Institute for Immunology, Immunology, Management, Bayer, Merck

BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, today announced the appointment of three new members to the Executive Team.

Key Points: 
  • "Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships.
  • We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy.
  • Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics.
  • For further information on the Executive Committee, visit www.treefrog.fr

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

Retrieved on: 
Thursday, November 9, 2023
University of Los Andes (Colombia), IPO, Biogen, Therapy, Tajikistan State University of Law, Business, & Politics, Tree, Doctor of Philosophy, MBA, Engineering, HEC Paris, Central Executive Committee (PAP), Politics, Growth, Trinity College, Medicine, Paris, Executive Committee, Business, Senior, University of Hamburg, Ethicon, University, Trinity College Dublin, Sanofi, International communication, La Jolla Institute for Immunology, Immunology, Management, Bayer, Merck

BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, today announced the appointment of three new members to the Executive Team.

Key Points: 
  • "Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships.
  • We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy.
  • Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics.
  • For further information on the Executive Committee, visit www.treefrog.fr

California Life Sciences announces 20th annual Pantheon Award winners

Retrieved on: 
Thursday, November 2, 2023
La Jolla Institute for Immunology, CLS, Avantor, Golden, AbbVie, Immunology, Pantheon, Patient, Westin St. Francis, SAN, Film industry

SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- SAN FRANCISCO, Calif., Nov 2, 2023 -- California Life Sciences (CLS), the state’s most impactful life sciences trade association, today announced the winners of its 20th annual Pantheon Awards.

Key Points: 
  • SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- SAN FRANCISCO, Calif., Nov 2, 2023 -- California Life Sciences (CLS), the state’s most impactful life sciences trade association, today announced the winners of its 20th annual Pantheon Awards.
  • "Congratulations to the winners of the 20th Annual Pantheon Awards,” said Mike Guerra, CLS president & CEO.
  • “They are shining examples of dedication to scientific advancement and innovation, and they inspire us to keep pushing boundaries in pursuit of new solutions for patients around the world.”
    The 2023 Pantheon Award winners, by category, are:
    Erica Ollmann Saphire, Ph.D., La Jolla Institute for Immunology – Academia, Non-Profit, & Research Award
    Pantheon is California’s largest life sciences award celebration that brings together more than 500 industry pioneers each year.
  • After the open nomination period, finalists were chosen by the 2023 Pantheon Advisory Committee, and winners were selected through a public voting campaign which received more than 2,000 votes.

Georgia Research Alliance Trustees Name New President and CEO

Retrieved on: 
Wednesday, September 27, 2023
Emory University, Private sector, La Jolla Institute for Immunology, IBD, University, Cardiovascular disease, Infection, Cancer, Georgia State University, State government, Research, Biomedical sciences, Georgia Research Alliance, GRA, Student, Entrepreneurship, Retirement, Trustee, Interdisciplinarity, School, Economic development, Immunology, Inflammatory bowel disease, Emory University School of Medicine, Management, Pharmaceutical industry

Atlanta, GA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Trustees of the Georgia Research Alliance voted today to appoint Timothy Denning, Ph.D., vice president for research and economic development at Georgia State University, as the fifth president and CEO of GRA.

Key Points: 
  • Atlanta, GA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Trustees of the Georgia Research Alliance voted today to appoint Timothy Denning, Ph.D., vice president for research and economic development at Georgia State University, as the fifth president and CEO of GRA.
  • Denning, who will take the helm of the Alliance November 1, has led research and commercialization through a period of historic growth at Georgia State.
  • Denning’s leadership at Georgia State reflects a breadth and depth of activity that accelerated an already-growing research enterprise.
  • “A hallmark of GRA’s working model is forging strong collaborations to grow research and entrepreneurship at Georgia’s universities,” says GRA President and CEO Susan Shows.

Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024

Retrieved on: 
Wednesday, September 20, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, MSD, Head, MBA, Phase II, Doctor of Philosophy, Journal, Patient, Potyvirus, Epitope, Merck, NEC, La Jolla Institute for Immunology, FRCP, University, HPV16, Research, Lung cancer, Merck & Co., De novo, University of Liverpool, CD8, Cervical cancer, CTL, Biology, Immunology, Phase, Safety, AACR, E6, Immune system, University of Lausanne, European Journal, KOL, European Journal of Cancer Prevention, Bank statement, AstraZeneca, E7, ASCO, Euronext Paris, Statutory auditor, Combined, Immunotherapy, Tumor microenvironment, Pharmaceutical industry, Vaccine, Computer data storage, Cancer, MD, TG4050, Transgene

We are planning together with our partner NEC to start a randomized Phase II trial in 2024.

Key Points: 
  • We are planning together with our partner NEC to start a randomized Phase II trial in 2024.
  • Transgene and NEC intend to start a randomized Phase II trial in the adjuvant setting of head and neck cancer in 2024.
  • Transgene is assessing all options to ensure data read out in 2024 from the trial as previously communicated.
  • The Board of Directors of Transgene met on September 20, 2023, and approved the financial statements for the six-month period ended June 30, 2023.

Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023

Retrieved on: 
Thursday, September 7, 2023
La Jolla Institute for Immunology, Janssen, CD73, CDTX, Doctor of Philosophy, Janssen Pharmaceuticals, DFC, Patient, SAN, Immunology, Therapy, Vaccine, Medical imaging, Pharmaceutical industry, MD

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced it will host a virtual R&D Day on Thursday, September 21, 2023 at 12:00 PM ET. To register for the event, click here.

Key Points: 
  • To register for the event, click here .
  • Cidara leadership will provide an update on its Cloudbreak® pipeline using its oncology DFCs and will provide insight into clinical development considerations for DFCs, focusing on CD73, chemokine receptors, and multispecific DFCs targeting solid tumors.
  • Stephen Schoenberger, PhD (La Jolla Institute for Immunology) will discuss the unmet needs in cancer immunotherapy.
  • Ezra Cohen, MD (Chief Medical Officer, Tempus) will highlight the potential role of drug-Fc conjugates (DFCs) to transform the oncology therapeutic landscape.

Microphysiological Systems Conference 2023: A Deep Dive into Technologies & Applications - Innovations in 3D-Culture, Organoids, and Organs-on-Chips fields (Orlando, Florida - July 26-27, 2023)

Retrieved on: 
Tuesday, July 4, 2023
Central Florida, City University of Hong Kong, La Jolla Institute for Immunology, University, Impact, Engineering, Organoid, Associate professor, University of Florida, Electrical engineering, AME Publishing Company, MPS, Organ (biology), Royal Army Medical Corps, Novo Nordisk, University of Central Florida, Integration, Cornell University, Conference, City University, 3D printing, Management, Medical imaging, Chemistry

DUBLIN, July 3, 2023 /PRNewswire/ -- The "Microphysiological Systems 2023: A Deep Dive into Technologies & Applications" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 3, 2023 /PRNewswire/ -- The "Microphysiological Systems 2023: A Deep Dive into Technologies & Applications" conference has been added to ResearchAndMarkets.com's offering.
  • Topics to be covered include 3D-cell based screening methods, high content screening, and analysis, the use of model systems, and novel approaches for physiologically-relevant analysis of cell systems as well as building these systems (MPS systems).
  • The host is honored that Professor Mike Shuler, Samuel B. Eckert Professor of Engineering at Cornell University and President of Hesperos will be Chairperson of this Conference.
  • Conference Attendees Receive Full Access to the Co-Located EV Conference for Maximal Networking and Scientific Exchange.

Space Summit 2023: Chips in Space - Focus on Organs-on-Chips Being Deployed on Board the International Space Station (ISS): (Orlando, Florida, United States - July 26-27, 2023)

Retrieved on: 
Monday, July 3, 2023
Central Florida, City University of Hong Kong, La Jolla Institute for Immunology, University, Impact, Associate professor, University of Florida, Electrical engineering, Royal Army Medical Corps, Novo Nordisk, University of Central Florida, Integration, City University, Pharmaceutical industry, Management, Chemistry

Jason Ekert, Head US Discovery Translational Technology, UCB Pharma, United States of America

Key Points: 
  • Jason Ekert, Head US Discovery Translational Technology, UCB Pharma, United States of America
    The Impact of Integrated Multi-Organ-Chip Systems in Substance Testing: Progress and Future Outlook
    James Hickman, Professor, Nanoscience Technology, Chemistry, Biomolecular Science and Electrical Engineering, University of Central Florida; Chief Scientist, Hesperos, United States of America
    Chia-Hung Chen, Associate Professor, City University of Hong Kong, Hong Kong
    Matthias von Herrath, Vice President and Senior Medical Officer, Novo Nordisk, Professor, La Jolla Institute, United States of America
    16:30 - Tissue Chips in Space: Modeling Human Disease States in Microgravity
    Michael Roberts, Chief Scientific Officer, International Space Station National Laboratory, United States of America
    Siobhan Malany, Associate Professor, University of Florida and Founder, Micro-gRx, United States of America

Kyowa Kirin Appoints Gunnar F. Kaufmann, Ph.D., as Chief Research Officer, North America

Retrieved on: 
Wednesday, June 21, 2023
Vaccine, Monoclonal antibody, La Jolla Institute for Immunology, Scripps Research, Society, University, Senior, Bachelor of Science in Human Biology, CSO, American Association for Cancer Research, Kyowa Kirin, Journal, CAR, American Society of Clinical Oncology, Patient, University of Greifswald, Potyvirus, Drug discovery, Human biology, Immunology, Spacecraft, Caregiver, TSE, University of Marburg, Pharmaceutical industry, Nursing, Science, Immunotherapy, Cancer, Chemistry, Research, Biology

PRINCETON, N.J., June 21, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company, today announced that Gunnar Kaufmann, Ph.D., has been named Chief Research Officer (CRO). Dr. Kaufmann joins Kyowa Kirin North America (KKNA) from Oncternal Therapeutics, Inc., where he served as Chief Scientific Officer. In his new role, Dr. Kaufmann will oversee KKNA's team of researchers based in La Jolla, CA, as well as the Open Innovation Department, which seeks external partnerships to accelerate drug discovery and the application of new biotechnologies. He also serves as an Adjunct Assistant Professor at The Scripps Research Institute in the Departments of Chemistry and Immunology and Microbial Science.

Key Points: 
  • Dr. Kaufmann Joins from Oncternal Therapeutics, Inc.
    PRINCETON, N.J., June 21, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company, today announced that Gunnar Kaufmann, Ph.D., has been named Chief Research Officer (CRO).
  • Dr. Kaufmann joins Kyowa Kirin North America (KKNA) from Oncternal Therapeutics, Inc., where he served as Chief Scientific Officer.
  • He also serves as an Adjunct Assistant Professor at The Scripps Research Institute in the Departments of Chemistry and Immunology and Microbial Science.
  • "Dr. Kaufmann's proven track record of leading drug discovery, research, and preclinical development will help Kyowa Kirin grow our future pipeline with new drug targets and therapeutic candidates that have the potential to address patients' unmet needs," said Yoshifumi Torii, Ph.D., Global Research Head of Kyowa Kirin.

Space Summit 2023: Chips in Space - Focus on Organs-on-Chips Being Deployed on Board the the International Space Station (ISS): (Orlando, Florida, United States - July 26-27, 2023) - ResearchAndMarkets.com

Retrieved on: 
Monday, June 19, 2023
Technology, Science, Hardware, Other Science, Central Florida, City University of Hong Kong, La Jolla Institute for Immunology, University, Impact, Associate professor, University of Florida, Electrical engineering, Royal Army Medical Corps, Novo Nordisk, University of Central Florida, Integration, City University, Pharmaceutical industry, Management, Chemistry

Jason Ekert, Head US Discovery Translational Technology, UCB Pharma, United States of America

Key Points: 
  • Jason Ekert, Head US Discovery Translational Technology, UCB Pharma, United States of America
    The Impact of Integrated Multi-Organ-Chip Systems in Substance Testing: Progress and Future Outlook
    James Hickman, Professor, Nanoscience Technology, Chemistry, Biomolecular Science and Electrical Engineering, University of Central Florida; Chief Scientist, Hesperos, United States of America
    Chia-Hung Chen, Associate Professor, City University of Hong Kong, Hong Kong
    Matthias von Herrath, Vice President and Senior Medical Officer, Novo Nordisk, Professor, La Jolla Institute, United States of America
    16:30 - Tissue Chips in Space: Modeling Human Disease States in Microgravity
    Michael Roberts, Chief Scientific Officer, International Space Station National Laboratory, United States of America
    Siobhan Malany, Associate Professor, University of Florida and Founder, Micro-gRx, United States of America